New data presented Monday at the Virtual ISPOR Europe 2020 conference underscore the growing prevalence of essential tremor and the need for devices like the Cala Trio.

Dr. Rohit Dhall, MD, Associate Professor of Neurology and Director of Neurodegenerative Disorders at the University of Arkansas discusses essential tremors (ET) and a new wrist-worn bioelectronic device, called the Cala Trio™

Cala Health has developed a product to treat a massive unmet need in medicine. In the United States, it’s estimated that 2.2% of the population suffers from essential tremor (ET). This condition, much like Parkinson’s Disease, causes involuntary sharking, particularly in the hands, but ET is much more widespread.

Bioelectronic company Cala Health released positive data from its ongoing PROSPECT trial demonstrating that a majority of patients using its FDA-cleared Cala Trio device reported a reduction in hand tremors.

For Kate Rosenbluth, founder and chief scientific officer of Cala Health, and Renee Ryan, its CEO, the painting is a reminder of why they do their work every day: to restore functionality — and even bring back the joy of life — for the estimated 7 million people in the U.S. living with the condition.

I sat in an occupational therapy office with electrodes stuck to my right hand, playing a game of Connect Four. Or at least I attempted to play, unsuccessfully, as I had for the last 10 weeks.

Wearables are a hot topic in medtech circles today. But are they really medtech? Cala Health’s Trio device for treating essential tremors underscores the challenges and opportunities that wearables represent when compared to traditional medical devices.

People who live with tremors know it can impact every part of your life. Essential tremor is a nervous system disorder that causes involuntary shaking. It can be hard to write legibly, and even eat or drink without spilling.

When I was an Innovation Fellow, doing needs finding with my team, I met a man whose hands shook so badly that he could no longer write a letter to his wife or drink a coffee with a friend. He had a severe form of a debilitating disorder called essential tremor.

Doctors from the University of Arkansas for Medical Sciences in Little Rock are looking into new ways to reduce and hopefully stop essential tremors for patients.

In the PROSPECT study, a wrist-worn neuromodulation device Cala Trio by CalaHealth, Inc. provided symptomatic relief for essential tremor (ET).

Using Cala Health’s non-invasive therapeutic device Cala Trio for 40 minutes twice daily effectively helped to reduce hand tremors within three months, results from a clinical study show.

Patient recruitment is usually the biggest challenge in conducting clinical trials. Thanks to the International Essential Tremor Foundation and their members, CalaHealth recently enrolled the largest therapeutic essential tremor study in record time.

Results of the landmark PROSPECT trial of the Cala Trio, a wrist-worn wearable neuromodulation device for essential tremor (ET), suggest that the device is safe and effective for the reduction of hand tremor in individuals with ET.

StartUp Health has been the most active investor in health innovation companies in 2019. And we’re not slowing down. Meet the latest Health Transformers to join our family.

Lux Capital Managing Partner and Co-Founder Josh Wolfe visits the headquarters of Lux portfolio company Cala Health in Burlingame, California and has a conversation with CEO Renee Ryan. You’ll get an inside look at how Cala is empowering people with chronic disease.

Cala Health CEO talks about the focus of Cala on using electricity as medicine by developing wearable electronics to treat tremors in the hands of essential tremor patients.

In this episode of DeviceTalks Weekly, Tom Salemi, editorial director of DeviceTalks events and content, visits with Renee Ryan, the CEO of neuromodulation startup Cala Health.

Digital Health 150 is CB Insights' annual ranking of the 150 most promising digital health startups in the world.

Cala Trio therapy took the GOLD award for Diagnostics & Disease Treatment in the Medical Device/Dental category. Among the nomination entries comprising the best products, services, and businesses in innovation for the year 2020, Cala Trio was chosen as a winner by a panel of over 3,000 leading business executives from around the world.

Based on its recent analysis of the North American essential tremor (ET) treatment market, Frost & Sullivan recognizes Cala Health, Inc. with the 2019 North American Technology Innovation Award for its Cala Trio™, a prescription-only, wrist-worn device.

We highlight 2020’s emerging trends to watch and high-momentum startups with world-changing potential. The past few decades have seen unprecedented levels of innovation, especially in what Peter Thiel calls the world of “bits,” or software, internet, and mobile technology.